News Headlines Article

Pricey hepatitis C drugs help Gilead eclipse big sales threshold
San Francisco Business Times

Gilead Sciences Inc. earnings zoomed past second-quarter Wall Street expectations, pushed along by its two groundbreaking but controversially priced hepatitis C drugs. The Foster City-based company (NASDAQ: GILD), led by CEO John Martin, said Tuesday that it earned just short of $4.5 billion, or $2.92 per share on a diluted basis, on $8.24 million of revenue. Analysts expected $2.71 per share on $7.6 billion of revenue, according to a consensus estimate by Thomson Reuters.